research News

CHENGDU, China — Clover Biopharmaceuticals, Ltd., a global commercial-stage biotechnology company, today announced positive preliminary safety, efficacy and pharmacokinetics data in a Phase Ⅰ clinical trial evaluating SCB-219M, an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein produced from CHO cells, for the treatment of cancer patients with chemotherapy-induced...
Madrid, Spain – Scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), working in collaboration with the Instituto de Investigación Biomédica de Barcelona (IRB Barcelona), have discovered a new immunotherapy strategy that reduces cancer recurrence in mouse experimental models. The study, published in Nature Communications, shows that a specific...
Madrid, Spain – Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body’s immune response against the tumor. Researchers at the Spanish National Cancer Research Center (CNIO) and the 12 de Octubre University Hospital in Madrid have developed a new...